Skip to main content

ALPS Medical Breakthroughs ETF (SBIO)

NYSEARCA: SBIO · IEX Real-Time Price · USD
46.04 0.20 (0.44%)
Oct 22, 2021 4:00 PM EDT - Market closed
Assets$206.24M
NAV$45.83
Expense Ratio0.50%
PE Ration/a
Shares Out4.50M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend DateDec 19, 2019
1-Year Return
-
Volume16,679
Open45.74
Previous Close45.84
Day's Range45.24 - 46.24
52-Week Low41.54
52-Week High64.04
Beta1.19
Holdings127
Inception DateDec 31, 2014

About SBIO

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Asset ClassPortfolio-Multi Asset
SectorHealthcare
RegionGlobal
IssuerALPS Holdings
Stock ExchangeNYSEARCA
Ticker SymbolSBIO
Index TrackedPoliwogg Medical Breakthroughs Index

Top 10 Holdings

28.52% of assets
NameSymbolWeight
Legend BiotechLEGN4.55%
Kodiak SciencesKOD3.42%
Cerevel TherapeuticsCERE3.29%
Vir BiotechnologyVIR3.07%
AlkermesALKS2.91%
TG TherapeuticsTGTX2.67%
Iovance BiotherapeuticsIOVA2.37%
Karuna TherapeuticsKRTX2.25%
Arena PharmaceuticalsARNA2.21%
CytokineticsCYTK1.78%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Dec 19, 2019$0.01585Dec 27, 2019
Dec 20, 2018$0.78406Dec 27, 2018
Dec 21, 2017$0.57949Dec 28, 2017
Full Dividend History

News

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

Sector ETF report for SBIO

1 month ago - Zacks Investment Research

September Turns Sour: Top ETF Areas of Last Week

Wall Street ended on a negative note last week just the week before that, strengthening the worth of the adage that September is historically the worst month of the year for stocks.

1 month ago - Zacks Investment Research

Drug Price Debate May Not Hinder Biotech ETFs After All

The issue of pharmaceuticals pricing reform — a long-time favorite discussion on Capitol Hill — is gaining momentum, and some healthcare assets are bearing that burden. For example, the ALPS Medical Bre...

1 month ago - ETF Trends

Biotech Stocks Have Colds, but They Can Heal

This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to purs...

1 month ago - ETF Trends

Size Up SBIO Ahead of Biotech Rebound

Large-cap biotechnology stocks finally have some momentum, but relative to the broader healthcare sector, biotech is a 2021 laggard. The situation is worse for smaller biotech stocks and the related exc...

1 month ago - ETF Trends

5 Sector ETFs That Beat the Market in August

Most of the rally was powered by a huge vaccination drive, upbeat corporate earnings and the Fed???s dovish comments that have renewed optimism for sustained global economic recovery.

Other symbols:BEDZBETZPFEREMXRIGZ
1 month ago - Zacks Investment Research

Best Small/Mid-Cap ETFs of Last Week

The Russell 2000 Index was a winner last week. These ETFs gained immensely last week.

Other symbols:MIDUPFESGDJSILJ
1 month ago - Zacks Investment Research

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Other symbols:BBCCNCRIBBJPFETRILXBI
2 months ago - Zacks Investment Research

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

Sector ETF report for SBIO

2 months ago - Zacks Investment Research

Will the Biotech Space Consolidate in the Back Half of the Year?

Industry analysts continue to posit that biotechnology consolidation is poised to accelerate through year-end – a scenario that could propel the ALPS Medical Breakthroughs ETF (SBIO) further forward. Wh...

3 months ago - ETF Trends

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

3 months ago - Kiplinger

Turn Healthcare Breakthroughs into ETF Gains with This Fund

Biotechnology has long been fertile territory for disruptive growth and innovation in the healthcare sector.  The ALPS Medical Breakthroughs ETF (SBIO) is one of the premier exchange traded funds to tap...

4 months ago - ETF Trends

Top-Performing Biotech ETFs of Last Week

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

4 months ago - Zacks Investment Research

Post-Pandemic Healthcare Could Feature More Biotech M&A

Experienced investors know that talk of mergers and acquisitions activity is a near constant in the healthcare industry. Due to the sluggish pace of deal-making last year owing to the onset of the coron...

4 months ago - ETF Trends

5 Small-Cap Sector ETFs Leading the Russell 2000 Rally

We have presented five ETFs from different sectors that have easily crushed the Russell 2000 Index over the past month.

Other symbols:CNBSPSCDPSCEPSCU
4 months ago - Zacks Investment Research

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Other symbols:BBCGNOMPBEXBI
4 months ago - Zacks Investment Research

As Biotech Consolidation Heats up, ‘SBIO' Could Be a Winner

Biotechnology equities are slumping to start 2021, with the S&P Biotechnology Select Industry Index down 10% year-to-date. Mergers and acquisitions activity, which are typically vibrant in the biotech s...

5 months ago - ETF Trends

7 Health-Focused ETFs To Buy Now For the Post-Covid Future

The healthcare sector outperformed in the past year due to the pandemic. Here are seven ETFs for your portfolio to look beyond Covid-19.

Other symbols:GERMIBBIHFRYHXLVARKG
5 months ago - InvestorPlace

Greater Regulatory Scrutiny Could Weigh on Biotech ETFs

Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthr...

Other symbols:IBBXBI
7 months ago - ETF Trends

5 Small-Cap ETFs at the Forefront of the 2021 Market Rally

We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.

Other symbols:BFTRCALFCNBSXSVM
8 months ago - Zacks Investment Research

Capture Medical Breakthroughs and Big Acquisition Bucks with ‘SBIO'

Already off to a strong start in 2021, the ALPS Medical Breakthroughs ETF (SBIO) extended the good vibes by jumping 9% in the first full trading week of February. SBIO focuses on small- and mid-cap comp...

8 months ago - ETF Trends

ALPS ‘SBIO' ETF: Trial Progress Meets Investing Success

Clinical trials are of the utmost importance to biotechnology investors, but not all exchange traded funds adequately address the phenomenon. The ALPS Medical Breakthroughs ETF (SBIO) takes a different ...

8 months ago - ETF Trends

Don't Miss Out on Rampant Biotech Mergers with the SBIO ETF

Large cap biotechnology companies are flush with cash, and they're on the prowl for takeover targets, a scenario that could bode well for the ALPS Medical Breakthroughs ETF (SBIO). SBIO focuses on small...

9 months ago - ETF Trends

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

9 months ago - Zacks Investment Research

Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021

After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...

Other symbols:IBBJXBI
9 months ago - ETF Trends